MedPath

Activating the frontal brain in schizophrenia: comparison of aripiprazole versus resperidone using functional magnetic resonance imaging

Completed
Conditions
chronic psychosis
Schizophrenia
10039628
Registration Number
NL-OMON31229
Lead Sponsor
niversitair Medisch Centrum Groningen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
44
Inclusion Criteria

People diagnozed for schizophrenia according to DSM-IV. They should not repsond to first choiche treatment or suffer from serious side effects.
Besides, healthy control without high education level.

Exclusion Criteria

Subjects with a psychiatric or neurologic disease other than schizophrenia, for which they have been treated. Presence of MRI incompatible implants. For safety reasons female participants who may be pregnant will be excluded.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Difference in brain activity of the prefrontal cortex between groups with<br /><br>different medication. Besides accuraty and reactiontimes during task<br /><br>performance and severeness of positive and negative symptoms.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>nvt</p><br>
© Copyright 2025. All Rights Reserved by MedPath